Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Effects of a nutraceutical multicomponent supplement (Vertilev®) in older people with chronic dizziness: a prospective, open-label, single-arm multicenter study.

Created on 05 Nov 2026

Authors

Augusto Pietro Casani, Nicola Ducci, Roberto Albera, Marco Benazzo, Luigi Califano, Francesco Comacchio, Andrea Gallo, Paolo Gamba, Giampiero Neri, Nicola Quaranta, Elisabetta Rebecchi, Roberto Teggi, Giorgio Ciprandi

Published in

Panminerva medica. Nov 05, 2026. Epub Nov 05, 2026.

Abstract

Chronic dizziness and postural instability are highly prevalent in the elderly population, affecting 10-30% of individuals over 65, substantially impairing quality of life and increasing fall risk. This condition, often called "presbystasis", arises from progressive deterioration of vestibular, visual, and proprioceptive inputs and is frequently associated with central microcirculatory disturbances. Food supplements with neuroprotective, antioxidant, and metabolic properties may represent a promising therapeutic strategy.
This prospective, open-label, single-arm, multicenter study evaluated the potential effects and tolerability of a multicomponent nutraceutical supplement (Vertilev®; Levante Srl, Florence, Italy) in patients with chronic dizziness. No control or placebo group was included; this was a single-arm pre-post study. Patients received Vertilev® (Levante Srl) 2 tablets/day for 90 days and were assessed at baseline (T0), and after 30, 60, and 90 days (T30, T60, and T90, respectively). Outcome measures included the Dizziness Handicap Inventory (DHI) total score and subscales (primary outcome), Visual Analog Scale (VAS) for dizziness self-assessment, VAS for anxiety/mood, Tinetti Performance-Oriented Mobility Assessment (POMA), and Timed Up and Go (TUG) test.
This study included 45 patients with chronic dizziness (aged ≥65 years; 20 males, 25 females). Statistically significant improvements were observed across all outcome measures during the 90-day follow-up period. The DHI total score decreased from 35.7±21.6 at T0 to 19.4±16.5 at T90, representing a 45.7% improvement (P<0.001). Significant reductions were observed in all DHI subscales at each time point. VAS dizziness decreased from 58.4±23.4 at T0 to 33.4±19.7 at T90 (P<0.001; Cohen's d=1.014). Tinetti total score improved from 19.3±5.9 at T0 to 21.8±5.5 at T90 (+13.1%; P=0.002; Cohen's d=0.457), and TUG improved from 11.9±2.9 s to 11.1±2.1 s at T90 (P=0.007; Cohen's d=0.228). Tolerability was excellent in all patients, with no adverse events reported. Forty of the 45 enrolled patients (88.9%) completed the T90 assessment; 5 patients withdrew from the study before the assessment.
During the 90-day supplementation period, significant and progressive improvements were observed in dizziness-related disability, postural stability, and gait performance in elderly patients with chronic dizziness. The excellent tolerability profile supports further investigation of Vertilev® (Levante Srl) as a nutraceutical option in the management of presbystasis and chronic vestibular disorders in older people. These findings are exploratory; effects relative to placebo or usual care cannot be established from this design.

PMID:
42986319
Bibliographic data and abstract were imported from PubMed on 05 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement